清晨好,您是今天最早来到科研通的研友!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您科研之路漫漫前行!

Tumor-Infiltrating Lymphocytes and Survival Outcomes in Early ERBB2-Positive Breast Cancer

医学 曲妥珠单抗 蒽环类 内科学 肿瘤科 危险系数 乳腺癌 化疗 比例危险模型 癌症 置信区间
作者
Maria Vittoria Dieci,Giancarlo Bisagni,Stefania Bartolini,Alessio Schirone,Luigi Cavanna,Antonino Musolino,Francesco Giotta,Anita Rimanti,Ornella Garrone,Elena Bertone,Katia Cagossi,Samanta Sarti,Antonella Ferro,Federico Piacentini,Enrico Orvieto,Melinda E. Sanders,Federica Miglietta,Davide Massa,Sara Balduzzi,Pierfranco Conté
出处
期刊:JAMA Oncology [American Medical Association]
卷期号:11 (4): 386-386 被引量:7
标识
DOI:10.1001/jamaoncol.2024.6872
摘要

Importance For patients with early ERBB2 (formerly HER2 )–positive breast cancer, there is a need to identify biomarkers to guide treatment de-escalation. Objective To evaluate the association of tumor-infiltrating lymphocytes (TILs) with distant disease-free (DDFS) and overall survival (OS) for patients with ERBB2 -positive early breast cancer. Design, Setting, and Participants The ShortHER randomized clinical trial was a multicentric trial in Italy that enrolled patients with ERBB2 -positive breast cancer from December 2007 to October 2013. Patients received 9 weeks or 1 year of adjuvant trastuzumab combined with chemotherapy. Tumor samples were evaluated for TILs. Herein, patients were evaluated at a median follow-up of 9 years, and data were analyzed from February 2023 to August 2024. Intervention Four cycles of anthracycline-based chemotherapy followed by 4 courses of taxanes combined with trastuzumab for 1 year (long arm) or 3 courses of taxanes combined with trastuzumab for 9 weeks followed by reduced-dose anthracycline-based chemotherapy for 3 courses (short arm). Main Outcomes and Measures The association of TILs with DDFS and OS was assessed with Cox models. Results Of 1253 patients enrolled in the ShortHER trial, 866 women (median [IQR] age, 56 [48-64] years) had evaluable TILs. In Cox models with relevant factors, each 5% TIL increment was associated with improved DDFS (hazard ratio [HR], 0.87; 95% CI, 0.80-0.95; P = .001) and OS (HR, 0.89; 95% CI, 0.81-0.98; P = .01). The 10-year OS rate was 91.3% for patients with TILs 20% or higher, 93.3% for patients with TILs 30% or higher, and 98.1% for patients with TILs 50% or higher, resulting higher vs lower TIL counterparts. Patients with TILs lower than 20% showed a better outcome with the long vs short treatment (10-year DDFS, 88.7% vs 81.0%), whereas patients with TILs 20% or higher showed the opposite (10-year DDFS, 87.1% vs 92.2%; P for interaction = .01). Similarly, patients with TILs 20% or higher had a 10-year OS rate of 89.3% in the long arm vs 93.1% in the short arm (HR, 0.36; 95% CI, 0.10-1.36); patients with TILs lower than 20% had a 10-year OS rate of 91.3% in the long arm vs 86.9% in the short arm (HR, 1.36; 95% CI, 0.82-2.23; P for interaction = .06). Conclusions and Relevance This follow-up analysis of the ShortHER randomized clinical trial is, to our knowledge, the first demonstration of an independent effect of TILs in terms of OS for patients with ERBB2 -positive early breast cancer treated with adjuvant chemotherapy and anti- ERBB2 therapy. Patients with TILs 20% or higher who de-escalated trastuzumab duration and chemotherapy dose were not exposed to an excess risk of distant relapse or death. Trial Registration EudraCT: 2007-004326-25
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
sponge完成签到 ,获得积分10
9秒前
仁爱的元槐完成签到,获得积分10
10秒前
眯眯眼的破茧完成签到,获得积分10
17秒前
XiaonanTang完成签到 ,获得积分10
30秒前
Karl完成签到,获得积分10
36秒前
zzz完成签到,获得积分10
41秒前
QQQQQQ完成签到 ,获得积分10
51秒前
谦让的沛芹完成签到,获得积分10
57秒前
rockyshi完成签到 ,获得积分10
59秒前
yx完成签到 ,获得积分10
1分钟前
称心的高丽完成签到 ,获得积分10
1分钟前
怕黑的夏之完成签到,获得积分10
1分钟前
n01W97的应助被科研通管家采纳,获得20
1分钟前
1分钟前
领导范儿的应助被科研通管家采纳,获得10
1分钟前
1分钟前
星辰大海的应助被科研通管家采纳,获得10
1分钟前
Maestro_S的应助被科研通管家采纳,获得10
1分钟前
共享精神的应助被科研通管家采纳,获得10
1分钟前
脑洞疼的应助被小小采纳,获得10
1分钟前
赘婿的应助被小小采纳,获得10
1分钟前
蔡勇强完成签到 ,获得积分10
1分钟前
王馨完成签到 ,获得积分10
1分钟前
Elsevier大王的应助被小小采纳,获得30
1分钟前
脑洞疼的应助被小小采纳,获得10
2分钟前
自然的妙梦完成签到,获得积分10
2分钟前
粗暴的画板完成签到,获得积分10
2分钟前
cdercder的应助被小小采纳,获得10
2分钟前
领导范儿的应助被依然灬聆听采纳,获得10
2分钟前
科目三的应助被小小采纳,获得10
2分钟前
诚心金渐基完成签到 ,获得积分10
2分钟前
独特的高山完成签到 ,获得积分10
2分钟前
田様的应助被小小采纳,获得10
2分钟前
wcl完成签到,获得积分10
2分钟前
孙文杰完成签到 ,获得积分0
2分钟前
万能图书馆的应助被小小采纳,获得10
2分钟前
可爱沛蓝完成签到 ,获得积分10
2分钟前
隐形曼青的应助被小小采纳,获得10
2分钟前
成就的翠芙完成签到,获得积分10
2分钟前
睡不醒完成签到 ,获得积分10
2分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8185453
求助须知:如何正确求助?哪些是违规求助? 9574168
关于积分的说明 21834496
捐赠科研通 7783045
什么是DOI,文献DOI怎么找? 3434570
关于科研通互助平台的介绍 2558912
邀请新用户注册赠送积分活动 2481326